NEW YORK(GenomeWeb) – Natera plans to offer 6.25 million shares of its stock in its initial public offering, raising up to $103.3 million in net proceeds, it said in a document filed with the US Securities and Exchange Commission today. 

In an amended Form S-1, the San Carlos, California-based non-invasive prenatal testing firm said it plans to price its shares at between $15 and $17. At the midpoint price of $16, net proceeds from the offering are anticipated to be $89.3 million, or $103.3 million if the underwriters exercise their overallotment option in full. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.

Sponsored by

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.

Sponsored by

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Sponsored by

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sponsored by

This webinar will discuss an approach for automating variant classification based on the American College of Medical Genetics and Genomics guidelines.